Polaryx Therapeutics, Inc. (PLYX)Healthcare | Biotechnology | Paramus, United States | NasdaqCM
2.06 USD
-0.05
(-2.370%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.15 +0.09 (4.369%) ⇧ (Aug. 28, 2026, 7:45 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:15 a.m. EDT
The immediate outlook is neutral-to-slightly-bearish as the stock trades flat against its 50-day moving average, showing no clear momentum edge despite recent volatility. However, the long-term investment case is severely compromised; the company is a biotech firm with negative earnings, negative free cash flow, and a return on equity of nearly -97%, indicating a business that is burning capital without generating returns. The price action confirms this deterioration, as the stock has fallen approximately 58% over the trailing 200 days, suggesting the market has already priced in significant distress. Furthermore, there is no dividend history to provide any income cushion, making this a pure speculative play on a failing balance sheet rather than a viable investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.255484 |
| AutoTheta | 0.266626 |
| AutoETS | 0.329418 |
| AutoARIMA | 0.709055 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 1.97 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.956 |
| Excess Kurtosis | 0.12 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 97,527,184 |
| Website | https://polaryx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.94114286 |
| Address1 | South Tower |
| Address2 | 140 E Ridgewood Avenue Suite 415 |
| All Time High | 48.91 |
| All Time Low | 1.85 |
| Ask | 2.59 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 130,360 |
| Average Daily Volume3 Month | 127,020 |
| Average Volume | 127,020 |
| Average Volume10Days | 130,360 |
| Bid | 1.52 |
| Bid Size | 2 |
| Book Value | 0.219 |
| City | Paramus |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.06 |
| Current Ratio | 13.53 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.138 |
| Day Low | 1.97 |
| Display Name | Polaryx Therapeutics |
| Ebitda Margins | 0.0 |
| Enterprise Value | 91,140,744 |
| Eps Trailing Twelve Months | -0.14 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.2726 |
| Fifty Day Average Change | -0.2126 |
| Fifty Day Average Change Percent | -0.09354924 |
| Fifty Two Week Change Percent | -94.11429 |
| Fifty Two Week High | 48.91 |
| Fifty Two Week High Change | -46.85 |
| Fifty Two Week High Change Percent | -0.9578818 |
| Fifty Two Week Low | 1.85 |
| Fifty Two Week Low Change | 0.20999992 |
| Fifty Two Week Low Change Percent | 0.11351347 |
| Fifty Two Week Range | 1.85 - 48.91 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,770,042,600,000 |
| Float Shares | 6,777,560 |
| Free Cashflow | -2,086,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 2 |
| Fullday Change | -0.05 |
| Fullday Change Percent | -2.36967 |
| Fullday Price | 2.15 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.69921994 |
| Held Percent Institutions | 0.04401 |
| Implied Shares Outstanding | 47,343,297 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-02-02 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey. |
| Long Name | Polaryx Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 97,527,184 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_414729746 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -6,849,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 104,178,125 |
| Number Of Analyst Opinions | 4 |
| Open | 2.09 |
| Operating Cashflow | -5,809,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 201 940 7236 |
| Post Market Change | 0.09000015 |
| Post Market Change Percent | 4.3689394 |
| Post Market Price | 2.15 |
| Post Market Time | 1,787,960,721 |
| Previous Close | 2.11 |
| Price Hint | 4 |
| Price To Book | 9.406392 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.221 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.05 |
| Regular Market Change Percent | -2.36967 |
| Regular Market Day High | 2.138 |
| Regular Market Day Low | 1.97 |
| Regular Market Day Range | 1.97 - 2.138 |
| Regular Market Open | 2.09 |
| Regular Market Previous Close | 2.11 |
| Regular Market Price | 2.06 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 85,848 |
| Return On Assets | -0.42519 |
| Return On Equity | -0.96559995 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 47,343,297 |
| Shares Percent Shares Out | 0.005 |
| Shares Short | 249,038 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 306,529 |
| Short Name | Polaryx Therapeutics, Inc. |
| Short Percent Of Float | 0.0115 |
| Short Ratio | 2.51 |
| Source Interval | 15 |
| State | NJ |
| Symbol | PLYX |
| Target High Price | 10.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 7.5 |
| Target Median Price | 7.0 |
| Total Cash | 11,542,000 |
| Total Cash Per Share | 0.232 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.14 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.153931 |
| Two Hundred Day Average Change | -2.0939312 |
| Two Hundred Day Average Change Percent | -0.5040842 |
| Type Disp | Equity |
| Volume | 85,848 |
| Website | https://polaryx.com |
| Zip | 7,652 |